The position is charged to uncover and develop competitive growth opportunities and works proactively to ensure healthcare economics and reimbursement challenges are managed shaping a positive business environment. Develops relationships with key thought leaders and proactively identifies business opportunities that can be incorporated into brand / pipeline business plans.  Develops and coordinates execution of activities in alliance development.

Accountabilities: 

• Coordinates with Cubist business segment leaders to align and incorporate in-line Product strategies and pipeline into policy objectives. 
• Expand Cubist's vision of its public sector model, including working with Strategic Planning, Corporate Development (relating to portfolio management) and Corporate Communications (relating to image / relationship building).
• Creates informatics system to track all corporate, business segment, brand interests and priorities in healthcare sector. Responsible for researching, investigating all issues that may have an impact on healthcare/access/reimbursement and business operations.
• Accountable for maintaining an external focus, proactively identifies issues and opportunities.
• Accountable for all healthcare impact analysis on relevant federal legislation, trends and healthcare reform measures that would affect company's business operations.
• Serves as an integrated strategic partner and resource for corporate and brand teams to develop and deliver comprehensive government affairs programs based on needs and objectives.
• Creates policy and develops strategy to support product objectives as well as overall corporate/business objectives. Drives tactics and execution to meet policy and strategic objectives that result in consistent corporate policy and directs implementation.
• Identifies with internal businesses (e.g., HEOR working group) the need to create compelling health care economics data and evidence to support increased access and favored reimbursement products
• Responsible for communicating impacts to appropriate departments and driving policy creation/strategy and implementation.
• Participates in the development and assessment of business strategy to identify communication opportunities and needs e.g. MRSA, CDAD/Gram Negative market pre-launch preparation
• Develops and maintains relationships with appropriate / relevant agencies (e.g., CMS / AHRQ / MedPAC) and Congressional staff
• Develops and maintains relationships with appropriate allied /alliance groups to position company's business growth opportunities within the Public sector and the broader Healthcare system.  
• Representing Cubist in DC-based trade association State-Government Affairs working groups and policy committees

Required Skills and Experience

• Education: Bachelor's degree required.  Pharm D, JD, MBA, Masters Public Policy desirable.
• Must have pharmaceutical business knowledge, reimbursement experience, understand principles of business and exhibits strategic thinking.
• Eight (8) + years business experience in reimbursement/government affairs development.
• Project management, public policy experience with government programs and managed markets experience is highly desirable
• Managerial experience and budget management desirable.
• Lobbying experience desirable.
• Understanding of Federal payer programs, health policy experience desirable.

• Work Environment: Office with approximately 20 -25 % travel required.

Physical Demands: None

To perform this job successfully, an individual must be able to perform each essential duty satisfactorily within the context of the representative work environment and physical demands described above.  Likewise, qualifications listed are representative of the knowledge, skills, and abilities required to perform the position's essential functions.  Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions. 

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM(R) I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV(TM)-1 and CONSERV(TM)-2 -- for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist, founded in 1992, is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

The Boston Globe ranked Cubist Pharmaceuticals, Inc. first among the "Top 100" Massachusetts-based publicly traded companies in its 21st annual "Globe 100" list.  Further, The Boston Globe named Cubist as one of the Top Places to Work in Massachusetts in 2008.  Cubist was ranked 36th on the overall list and 13th on the midsized company list.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.  AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.

SOURCE: PUBLIC AFFAIRS COUNCIL 10/05/09